Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between …

JA Bonner, PM Harari, J Giralt, RB Cohen… - The lancet …, 2010 - thelancet.com
Background Previous results from our phase 3 randomised trial showed that adding
cetuximab to primary radiotherapy increased overall survival in patients with locoregionally …
被引用次数：2480 相关文章

Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between …

JA Bonner, PM Harari, J Giralt, RB Cohen… - The Lancet …, 2010 - infona.pl
Previous results from our phase 3 randomised trial showed that adding cetuximab to primary
radiotherapy increased overall survival in patients with locoregionally advanced squamous …

Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between …

JA Bonner, PM Harari, J Giralt… - The Lancet …, 2010 - pubmed.ncbi.nlm.nih.gov
Background Previous results from our phase 3 randomised trial showed that adding
cetuximab to primary radiotherapy increased overall survival in patients with locoregionally …

Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between …

JA Bonner, PM Harari, J Giralt, RB Cohen… - The Lancet …, 2009 - europepmc.org
Background Previous results from our phase 3 randomised trial showed that adding
cetuximab to primary radiotherapy increased overall survival in patients with locoregionally …

Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between …

JA Bonner, PM Harari, J Giralt… - The lancet …, 2010 - mdanderson.elsevierpure.com
Background: Previous results from our phase 3 randomised trial showed that adding
cetuximab to primary radiotherapy increased overall survival in patients with locoregionally …

Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between …

JA Bonner, PM Harari, J Giralt, RB Cohen… - The Lancet …, 2010 - thelancet.com
Background Previous results from our phase 3 randomised trial showed that adding
cetuximab to primary radiotherapy increased overall survival in patients with locoregionally …

[引用][C] Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between …

JA BONNER - Lancet Oncol., 2009 - cir.nii.ac.jp
Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer : 5-year
survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and …

[引用][C] Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between …

JA Bonner, PM Harari, J Giralt, RB Cohen… - The Lancet …, 2010 - portalrecerca.uab.cat
Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year
survival data from a phase 3 randomised trial, and relation between cetuximab-induced …

[引用][C] Matter of Survival.

TN Bonner - College and University Journal, 1972 - ERIC
ERIC - EJ066241 - Matter of Survival, College and University Journal, 1972 NotesFAQContact
Us ERIC - Institute of Education Sciences Collection Thesaurus Advanced Search Tips Peer …

Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between …

JA Bonner, PM Harari, J Giralt, RB Cohen, CU Jones… - The Lancet …, 2010 - Elsevier
BACKGROUND: Previous results from our phase 3 randomised trial showed that adding
cetuximab to primary radiotherapy increased overall survival in patients with locoregionally …